http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0300099-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bef96a52ca9eaf6230a857ba74af9a1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2001-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90b552285538d7822bc631f83a7f209c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cd4f6d01a96d0824a933ff66c95a293 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a5cd2c7164e5da28719ca96ecb77aaa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f5cd46577f0ea0cae33be8539b4eddc |
| publicationDate | 2003-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0300099-A2 |
| titleOfInvention | Vaccine for the treatment of artherosclerosis |
| abstract | The present invention relates to novel vaccine therapies and to the prophylactic treatment of atherosclerotic diseases. Accordingly, the present invention provides immunogens comprising apolipoproteins or fragments or derivatives thereof, which in their native form have at least one activity of total apolipoprotein, such as: (a) inhibiting apolipoprotein B receptor binding, and / or (b) lipoprotein lipase. An example of such an apolipoprotein is preferably apolipoprotein C-III (ApoCIII). The immunogen-containing vaccines of the invention are effective for the long-term prevention or reduction of atherosclerotic plaque formation, thereby reducing the possibility of atherosclerosis leading to coronary or cerebrovascular disease. which comprises administering an agent that results in a selective inhibition of apolipoprotein activity in man. The present invention relates to methods for treating or preventing chimeras by active vaccination or passive vaccination comprising administering to a patient an antibody that selectively binds to an apolipoprotein having at least one activity: (a) Apolipoprotein B and / or its receptor b) inhibition of lipoprotein lipase; and in this aspect of the invention, the antibody preferably binds to ApoCIII and abolishes ApoCIII activity. The invention further relates to the use of immunogens according to the invention in a medicament and to methods for their preparation. SHE |
| priorityDate | 2000-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 325.